ReviewMolecular oncology2009
Role of genetic polymorphisms and ovarian cancer susceptibility.
Review in Molecular oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 84 citations in OpenAlex.
- CHST9 rs1436904 genetic variant contributes to prognosis of triple-negative breast cancer.Scientific reports · 2017Trial
- Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients.BioMed research international · 2014Trial
- Impact of single nucleotide variants in estrogen genes on ovarian cancer risk: a systematic review and meta-analysis.Endocrine oncology (Bristol, England) · 2025Review
- RIPK1 polymorphisms and expression levels: impact on genetic susceptibility and clinical outcome of epithelial ovarian cancer.Cancer cell international · 2023Article
- The association between TIPARP gene polymorphisms rs2665390 and ovarian cancer susceptibility.Gynecologic oncology reports · 2023Article
- Article
- Article
- MassArray analysis of genomic susceptibility variants in ovarian cancer.Scientific reports · 2020Article
- Integration of Population-Level Genotype Data with Functional Annotation Reveals Over-Representation of Long Noncoding RNAs at Ovarian Cancer Susceptibility Loci.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017Article
- Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration.Oncotarget · 2016Article
- Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk.Human molecular genetics · 2016Article
- Increasing sensitivity to DNA damage is a potential driver for human ovarian cancer.Oncotarget · 2016Article
- STAT3 polymorphisms may predict an unfavorable response to first-line platinum-based therapy for women with advanced serous epithelial ovarian cancer.International journal of cancer · 2016Article
- Endometriosis as a risk factor for ovarian or endometrial cancer - results of a hospital-based case-control study.BMC cancer · 2015Article
- Breast Cancer Update 2014 - Focus on the Patient and the Tumour.Geburtshilfe und Frauenheilkunde · 2015Article
- A Single Nucleotide Polymorphism in Catalase Is Strongly Associated with Ovarian Cancer Survival.PloS one · 2015Article
- Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network.Geburtshilfe und Frauenheilkunde · 2015Article
- Estrogen receptor alpha (ERS1) SNPs c454-397T>C (PvuII) and c454-351A>G (XbaI) are risk biomarkers for breast cancer development.Molecular biology reports · 2014Article
- Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2014Article
- Systemic Lupus Erythematosus: Old and New Susceptibility Genes versus Clinical Manifestations.Current genomics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 10 institutions in 4 countries.
Funding
Abstract
The value of identifying women with an inherited predisposition to epithelial ovarian cancer has become readily apparent with the identification of the BRCA1, and BRCA2 genes. Women who inherit a deleterious mutation in either of these genes have a very high lifetime risk of ovarian cancer (10-60%) and to some extent, increased risks of fallopian tube and peritoneal cancer. These highly lethal cancers are almost completely prevented by prophylactic salpingoophorectomy. BRCA1/2 mutation testing has become the accepted standard of care in families with a strong history of breast and/or ovarian cancer. This approach has the potential to reduce ovarian cancer mortality by about 10%. Although the ability to perform genetic testing for BRCA1 and 2 represents a significant clinical advance, the frequency of mutations in these high penetrance ovarian cancer susceptibility genes is low in most populations. There is evidence to suggest that ovarian cancer susceptibility might be affected by common low penetrance genetic polymorphisms like it was shown for several common disorders like diabetes or breast cancer. Although such polymorphisms would increase risk to a lesser degree, they could contribute to the development of a greater proportion of ovarian cancers by virtue of their higher frequencies in the population. It has been shown that the most powerful approach to studying low penetrance genes is an association study rather than a linkage study design. This review describes the efforts that have been made in this field by individual case-control studies and through multi-center collaborations as part of international consortia such as the Ovarian Cancer Association Consortium (OCAC).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.